The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper.

ABSTRACT:

Introduction

Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer.

Methods and analysis

The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthal

SUBMITTER: Smith JR 

PROVIDER: S-EPMC9341180 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature